DPP-4 inhibitors improved the impaired spatial learning and memory, decreased tau and NFs aggregation, increased Aβ degradation and reversed AD-like neurodegeneration through partial improvement of GLP-1 signaling pathway including PI3K-Akt and MAPK. Here, AKT1 is linked to Alzheimer disease.